摘要
目的探讨并评估晚期非小细胞肺癌的临床治疗中予以尼妥珠单抗靶向治疗与常规化疗方案联合应用的有效性及安全性。方法遴选时段2018年1月-2020年12月内80例晚期非小细胞肺癌患者,根据治疗方式差异性设置分组,常规化疗方案40例(对照组),化疗+尼妥珠单抗靶向治疗40例(研究组),对疾病总控制率、不良反应率等指标对比分析。结果研究组临床总控制率更高,WHOQOL-BREF生活质量评分高,不良反应发生率更低,均较之对照组(P<0.05)。治疗后2组血清肿瘤标记物(CYFRA21-1、NSE、CEA)水平均大幅度下降,同时研究组较对照组降低幅度更为显著(P<0.05)。结论晚期非小细胞肺癌采纳尼妥珠单抗靶向治疗与常规化疗联合应用,可取得理想的治疗效果,对疾病予以有效控制及改善,实现提高预后的目标。
Objective To evaluate the efficacy and safety of the combination of nituzumab targeted therapy with conventional chemotherapy in the treatment of advanced non-small cell lung cancer.Methods 80 patients underging advanced non-small cell lung cancer from January 2018 to December 2020 were selected.According to the different treatment,40 patients treated with routine chemotherapy were chosen as control group,while 40 patientstreated with chemotherapy-induced nituzumab were divided into study group.The total controlling rate and adverse reaction rate were compared and analyzed.Results Compared with the control group,the overall clinical controlling rate in the study groupwas higher,WHOQOL-BREF Quality of Life Score were also high in the study group,the incidence of adverse reactions was lower in the study group(P<0.05).The level of serum tumor markers(CYFRA21-1、NSE、CEA)decreased significantly between the two groups after treatment,and the decrease in the study group was more significant than that in the control group(P<0.05).Conclusion The combination of nituzumab targeted therapy with conventional chemotherapy can achieve ideal therapeutic effect,effectively control the disease,and achieve the goal of improving prognosis.
作者
丁辉
DING Hui(Department of General Medicine Section,The Friendship Hospital of Urumqi,Urumqi,830046,China)
出处
《新疆医学》
2022年第8期904-906,956,共4页
Xinjiang Medical Journal
作者简介
丁辉,男,主治医师,研究方向:临床全科医学,老年病。
